Most Read Articles
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Emerging role of lipoprotein(a) lowering for CVD risk reduction

10 Oct 2018

Pathophysiological, epidemiological and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal, independent risk factor for cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). [J Am Coll Cardiol 2017;69:692-711]

According to Professor Sotirios Tsimikas from the University of California San Diego, US, the estimated global population with elevated Lp(a) >50 mg/dL is 1.43 billion, and the associated risk is consistent across a broad spectrum of patients, including those with LDL-cholesterol <70 mg/dL. Hence, clinical guidelines now recommend considering Lp(a) screening and treatment for high-risk individuals, such as those with familial hypercholesterolaemia, or those with recurrent CVD despite optimal lipid lowering. [J Am Coll Cardiol 2018;71:177-192; Eur Heart J 2016;37:2999-3058]

Current therapies such as mipomersen and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower Lp(a) by 20–30 percent, but are not indicated for Lp(a) lowering as such.  Emerging RNA-targeted therapeutics are the first to be specifically evaluated in randomized trials of Lp(a) lowering in individuals with high baseline Lp(a).

“Results are promising. For instance, the antisense oligonucleotide [ASO] IONIS-APO(a) produced dose-dependent reductions in Lp(a) levels of around 80 percent, with no apparent safety concerns,” reported Tsimikas. [Lancet 2016;388:2239-2253] Another ASO, AKCEA-APO(a), is now under phase I trial. [https://clinicaltrials.gov/ct2/show/NCT03070782]

“Specific therapies currently in clinical development will allow us to test the Lp(a) hypothesis that lowering elevated Lp(a) levels will lead to improved clinical outcomes,” he concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.